October 29, 2020

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): immunity, treatment

• A phase 2 randomized placebo-controlled trial (n=452) interim analysis found that patients who received a 2800mg dose of monoclonal antibody LY-CoV555 could reduce SARS-CoV-2 log viral load by 3.4-fold after 11 days compared to patients receiving placebo, corresponding to a 0.53 log viral load reduction (95% CI: -0.98 to -0.08). Other patients receiving a 700mg dose (n=101) or a 7000mg dose (n=101) experienced smaller differences.

Chen et al. (Oct 28, 2020). SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2029849